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Abstract
Alzheimer disease (AD) is a complex pathology related to multiple causes including oxidative stress. Brain-derived
neurotrophic factor (BDNF) is a neutrotrophic factor essential for the survival and differentiation of neurons and is
considered a key target in the pathophysiology of various neurodegenerative diseases, as for example AD.
Contrarily to BDNF, the precursor form of BDNF (proBDNF) induces apoptosis through the specific interaction with
p75 and its co-receptor, Sortilin.
We used hippocampal tissue and cerebrospinal fluid from AD patients and controls. to study the localization and
the levels of proBDNF, p75 and Sortilin as well as the post-traduccional modifications of proBDNF induced by
Radical Oxygen Species, by immunofluorescence and Western blot. Differentiation and survival were assessed on
differentiated mouse hippocampal neurons derived from postnatal neural stem cells from WT animals or from the
transgenic AD animal model APP/PS1ΔE9, based on mutations of familiar AD. In AD patients we observe a
significative increase of proBDNF and Sortilin expression and a significative increase of the ratio proBDNF/BDNF in
their cerebrospinal fluid compared to controls. In addition, the proBDNF of AD patients is modified by ROS-derived
advanced glycation end products, which prevent the processing of the proBDNF to the mature BDNF, leading to
an increase of pathogenicity and a decrease of trophic effects. The cerebrospinal fluid from AD patients, but not
from controls, induces apoptosis in differentiated hippocampal neurons mainly by the action of AGE-modified
proBDNF present in the cerebrospinal fluid of the patients. This effect is triggered by the activation and processing
of p75 that stimulate the internalization of the intracellular domain (ICD) within the nucleus causing apoptosis.
Induction of apoptosis and p75 ICD internalization by AD patients-derived proBDNF is further enhanced in neuron
cultures from the AD model expressing the APP/PS1ΔE9 transgene.
Our results indicate the importance of proBDNF neurotoxic signaling in AD pathology essentially by three
mechanisms: i) by an increase of proBDNF stability due to ROS-induced post-traductional modifications; ii) by the
increase of expression of the p75 co-receptor, Sortilin and iii) by the increase of the basal levels of p75 processing
found in AD.
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Background
Alzheimer’s disease (AD) is a neurodegenerative dis-
order characterized by episodic memory decline at
onset and deficits in multiple cortical functions in
later stages. Neuropathology hallmarks are senile pla-
ques and neurofibrillary tangles accompanied by defi-
cits in axonal transport, synaptic dysfunction, and
neuronal loss. The exact molecular mechanisms that
trigger AD pathogenesis and disease course are not
entirely understood. Among them, the increase of oxi-
dative stress related to aging seems to play a central
role, not only in AD but also in other neurodegenera-
tive diseases [1]. There has been much research into
the possible involvement of neurotrophins in AD
pathogenesis, including Nerve Growth factor (NGF)
and Brain Derived Neurotrophic Factor (BDNF) [2].
This interest was further supported by studies dem-
onstrating the neuroprotective activity against neuro-
degeneration in different animal models of several
neurodegenerative diseases, including AD, which sug-
gested therefore a promising therapeutic role for neu-
rotrophins [3].
BDNF binds to TrkB tyrosine kinase receptor to trig-
ger the neurotrophic signaling including neuron sur-
vival, differentiation and synaptic plasticity of various
nerve cell populations during normal development and
during tissue repair after injury [4, 5]. BDNF is synthe-
sized as a precursor form (proBDNF) that is processed
by the activity of several proteases rendering three main
products of 14 kDa (mature BDNF), 28 kDa and
34 kDa [6]. ProBDNF was reported to be biologically
active and, unlike BDNF, it was shown to induce apop-
tosis through its interaction with p75 and its
co-receptor, Sortilin [6–11]. p75 belongs to the family
of tumor necrosis factor receptors, has not catalytic ac-
tivity but a conserved non functional death domain
[12]. The signaling mechanisms of p75 are complex and
involve several intracellular interactors which trigger
specific effects including Sc1, NRAGE and Necdine
(cell cycle arrest) [13], RhoA (neuritogenesis) [12] and
NRIF (apoptosis) [14]. An important signaling event for
p75 involved in apoptosis is the processing of the re-
ceptor by convertases, in particular by a α-protease
(BACE1) followed by a γ-secretase activity (presenilin 1
or PS1), that yield a 20 kDa intracellular domain
(p75ICD) that is translocated into the nucleus [15–18].
p75ICD regulates the activity of the transcription factor
NRIF inducing apoptosis [19]. Besides all these
functions, p75 has also been reported to act as a
co-receptor for Trk, indicating that p75 plays a central
role in integrating the neurotrophic effects triggered by
neurotrophins (as Trk co-receptor) and the pro-apop-
totic signaling triggered by pro-neurotrophins (as Sorti-
lin co-receptor).
In normal brains, the pro-apoptotic function of pro-
neurotrophins and the neurotrophic effects of mature
neurotrophins are tightly controlled by their expres-
sion levels as well as by the expression levels of their
receptors, in particular p75 which is crucial for the
integration of the two effects. It is conceivable there-
fore that neurodegeneration during AD might be
caused by an imbalance of survival and death mecha-
nisms due to changes in the relative levels of these
proteins. Accordingly, the cerebral cortex of AD pa-
tients showed increased levels of p75 [20, 21] con-
comitant with decreased levels of Trk receptors which
will favor an apoptotic signaling [22–24]. BDNF sig-
naling was also shown to be altered in AD as an spli-
cing form of TrKB, which gives rise to a truncated
form of the receptor lacking the tyrosine kinase do-
main (presumably acting as a dominant negative), is
expressed predominantly in hippocampus and frontal
cortex in AD [23]. On the other hand, several works
have described a reduced concentration of BDNF in
the CSF of AD-affected patients [24]. Paradoxically,
some authors have shown a decrease of proBDNF ex-
pression in AD-affected human brains [25, 26]. How-
ever, in the CSF of AD-affected patients, the levels of
proBDNF have not been analyzed yet. Moreover, there
is no data in the literature about the relative levels of
proBDNF and BDNF in the CSF of AD-affected indi-
viduals compared to controls.
The relative levels of proBDNF and BDNF are directly
regulated by the activity of the proteases involved in
their processing. We have previously shown that
proNGF extracted from brains of AD patients was more
resistant to be processed by convertases in comparison
to the proNGF isolated from control brains [27, 28].
We reported that the relative stability of proNGF in
AD brains was due to post-traduccional modifications
as a consequence of an increase of oxidative stress in
the affected tissue [28]. In particular, we observed that
Glyoxal (GO) and methylglyoxal (MGO), two highly re-
active dicarbonyls that are increased during OS, reacted
with free amino groups of Lys, Arg and Cys residues in
proNGF, leading to the formation of the AGE/ALE ad-
ducts Nε-(carboxymethyl)-lysine (CML), Nε-(carbox-
yethyl)-lysine (CEL) and intermolecular crosslink and
making proNGF in AD patients more resistant to the
action of convertases [28].
In the present work we have studied the relative levels
of BDNF and proBDNF and their receptors in AD pa-
tients and found a significant increase of Sortilin and
proBDNF in the hippocampus. We also detected a sig-
nificant increase of the ratio proBDNF/BDNF in the CSF
of the AD patients, which shows a good correlation with
the pathogenic effect of the pro-neurotrophin in the
brain. Interestingly, the proBDNF in the CSF of AD
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patients showed an increase of CEL modifications
which account for the increase of the proBDNF/
BDNF ratio due to the major stability of the modified
pro-form. Stimulation of primary cultures of hippo-
campal neurons with CSF from AD patients increased
significantly the apoptotic cell death and the nuclear
localization of p75ICD compared with the CSF from
controls. Similar effects were observed when neurons
were stimulated with a proBDNF that was modified
in vitro by MGO. Importantly apoptosis and p75ICD nu-
clear localization were strongly reduced when the CSF of
AD patients was immunodepleted of proBDNF, indicating
that these effects were mediated, to a large extent, by the
presence of proBDNF in the CSF. Finally, we demonstrated
that the modified proBDNF had a stronger effect on apop-
tosis and p75ICD nuclear localization on primary cultures
of hippocampal neurons obtained from a transgenic AD
mouse model expressing the APP/PS1ΔE9 transgene. In
summary, we propose that in AD, proBDNF-p75/Sortilin
signaling has an important contribution to the pathogenesis
of the disease, causing an increase of cell death and impair-
ing neuronal differentiation.
Methods
Human brain samples
Brain samples were obtained from the Institute of
Neuropathology, Bellvitge University Hospital. Brain tis-
sue was obtained from the Institute of Neuropathology
HUB-ICO-IDIBELL Biobank and the Hospital Clinic-
IDIBAPS Biobank following the guidelines of Spanish le-
gislation on this matter (Real Decreto de Biobancos
1716/2011) and approval of the local ethics committees.
At autopsy, one hemisphere was rapidly cut in coronal
sections 1 cm thick and selected areas of the encephalon
were dissected, frozen on dry ice, and stored at − 80 °C
in labeled plastic bags until use. The other hemisphere
was fixed by immersion in 4% buffered formalin for
three weeks for morphologic examination. The neuro-
pathological study was carried out on twenty-five regions
of the cerebral cortex, diencephalon, thalamus, brain-
stem, and cerebellum. De-waxed paraffin sections were
stained with hematoxylin and eosin and Klüver-Barrera
and processed for immunohistochemistry to microglia-
specific markers, glial fibrillary acidic protein, β-amyloid,
phosphorylated tau, α-synuclein, TDP-43, ubiquitin, and
p62. Neuropathological diagnosis of the AD was carried
out following the Braak, and Braak stages [29] adapted
to paraffin sections [30]. Cases with concomitant path-
ologies, including Lewy body diseases, tauopathies (par-
ticularly argyrophilic grain disease), vascular diseases,
TDP-43pathies, and metabolic syndrome were excluded.
Control and disease cases were processed in parallel.
The anterior hippocampus area was used for further im-
munohistochemical studies.
Human CSF samples
CSF samples were obtained from control and
AD-affected patients and maintained at 4 °C for less
than 4 h. All patients have signed informed consent and
the study has been approved by the hospital’s ethics
committee. All patients underwent lumbar puncture be-
tween 8:00 and 10:00 in the morning to avoid variations
relating to the circadian rhythm. Protein concentration
was determined by DC-Protein Assay (Bio-Rad). Sam-
ples were collected and frozen in polypropylene tubes.
Post-puncture, CSF was centrifuged at 2000 g for
10 min at 4 °C and stored at − 80 °C until the use of the
samples. The levels in CSF Aβ42, t-tau and p-tau were
determined by a method of enzyme-immuno assay
(ELISA) using the kit Innotest Amyliod β (1–42), Innot-
est htau and phospho-tau 181 (Innogenetics ®) according
to the manufacturer’s instructions. All samples were
measured in duplicate and were expressed as pg/ml. We
use cut off points based on the calculation of sensitivity
and specificity of our own study population (different
from this sample).
Animal model
APPswe/PS1DE9 with a C57Bl/6 background (double
transgenic mice expressing a chimeric mouse/human
amyloid precursor protein and a mutant human PS1
with deletion in exon 9) were purchased from The Jack-
son Laboratory and kept in specific pathogen free condi-
tions under standard animal housing conditions in a
12-h dark–light cycle with free access to food and water
in the animal house facility of the Universitat de Lleida
[31, 32]. Heterozygous males were bred with wild-type
C57/Bl6 females. Animal procedures were conducted ac-
cording to ethical guidelines (European Communities
Council Directive 86/609/EEC) and approved by the
local ethics committee of the Universitat de Lleida. For
experiments, tail biopsies were taken from P0 offsprings
for genotyping by PCR according to the PCR conditions
suggested by The Jackson Laboratory. Mice not express-
ing the transgene were used as controls.
Cell culture
Hippocampal Neural Stem Cells (NSCs) were isolated from
neonatal pups (P0–P1) from controls and APP/PS1
transgenic mice. Briefly, the brains were dissected in Hanks
Medium 1X (Gibco 11,039–021) supplemented with
Penicillin-Streptomycin (P/S) (1%) (Sigma-Aldrich P4333).
After dissection, the hippocampi were washed with Hanks
Medium with P/S (1%) and dissociated in Hanks Medium
with Papain (Sigma-Aldrich 1,001,992,754) for 20 min at
37 °C. Papain activity was stopped with two washes with
Trypsin inhibitor (10 mg/ml in Hanks medium) (Roche
Diagnostics 10,109,886,001) plus three washes with 1 ml of
Dulbecco’s modified Eagle’s medium (DMEM)/F12,
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supplemented with B27 (2%) (Gibco 12,587–010) and P/S.
Mechanical dissociation was performed with a
heat-rounded Pasteur pipette tip. Dissociated cells were
centrifuged at 600 rpm for 4 min, and the pellet was resus-
pended in DMEM/F12 (37 °C) supplemented with B27
(2%), P/S(1%), Epidermal Growth Factor (EGF) (20 μg/ml)
(Sigma-Aldrich E9644) and Fibroblast Growth Factor
(FGF) (20 μg/ml) (Alomone Labs F-170). Cells were platted
on bacterial, non-treated, P35 plates and incubated for four
days at 37 °C. After four days, the supernatant was centri-
fuged at 600 rpm for 4 min, the supernatant was removed
and the pellet was washed in complete medium DMEM/
F12 (37 °C) supplemented with B27 (2%) and P/S (1%),
without growth factors. Then the neurospheres were disso-
ciated with a pipette in 500 μl of complete medium and de-
termined the cell concentration by Trypan Blue dye
exclusion. Cells were plated at 6000 cells/well concentra-
tion in 8-well on a glass slide coated with poly-D-lysine
(Sigma-Aldrich P-7886) and laminin (Invitrogen 23,017–
015) with complete medium (DMEM/F12, B27 (2%) and
P/S (1%)). Neurons were treated at 1 DIV. Treatments
were done after two washes with DMEM/F12 without B27.
The treatments with neurotrophins and controls are done
with DMEM/F12 containing 0,25% B27. For treatments
with CSF, all the media is substituted by CSF from controls
and AD with P/S (1%). After six days (7 DIV in total), were
fixed for 30 min in 4% (w/v) paraformaldehyde (PFA)/PBS
for immunofluorescence assays.
Western blotting
CSF samples were obtained as described in 2.2., from con-
trol and AD-affected patients and maintained at 4 °C for
less than 4 h. Previously to the western blotting, CSF sam-
ples were concentrated 20X using Amicon Ultra 10,000
MWCO (Ultracel Low Binding Cellulose) (Millipore).
Protein concentration was determined by DC-Protein
Assay (Bio-Rad). Proteins were separated by electrophor-
esis in 12% SDS-PAGE and transferred to Immobilon-P
membranes (Millipore). Membranes were blocked for 1 h
at room temperature in TBS-T (50 mM Tris, pH 8.0;
133 mM NaCl, 0.2% Tween 20) with 5% skimmed milk
and incubated with primary antibodies against the mature
BDNF (1:1000 in TBS-T (Alomone) at 4 °C overnight and
with HRP-conjugated secondary antibodies (Jackson)
(1:5000 in TBS-T) at room temperature for 1 h. Detection
was performed using an ECL chemiluminescence system
(Amersham-Pharmacia) following the manufacturer’s in-
structions. For densitometry analysis of the immunoreac-
tive bands, we used ImageJ (http://rsbweb.nih.gov/ij/) with
local background subtracted. For each sample, the relative
abundance of each BDNF isoform was expressed as a ratio
of that particular BDNF isoform related to the total BDNF
signal (sum of proBDNF and mature BDNF). The data
were shown as the mean ± standard deviation (SD).
Differences between groups were calculated using a
2-tailed Student’s t-test.
AGE modifications of recombinant proBDNF
Recombinant human proBDNF (Alomone) was modified
by the reactive carbonyl specie MGO that react with free
amino groups of Lys residues on proteins, leading to the
formation of CEL adducts and intermolecular crosslinks
[28]. The reactions were performed for 24 h at 37 °C by
mixing 500 μg recombinant protein with 250 μl 50 μM
GO or MGO and 250 μl 100 mM sodium phosphate.
The modified proBDNF was dialyzed using Amicon
Ultra-4 Centrifugal Filter Units (Millipore) to remove
the excess of MGO and replace the solution with PBS.
Immunohistochemistry
Microtome sections of fixed and paraffin-embedded hu-
man hippocampus 30 μm thick were processed
free-floating, and collected in slides. Before immunodetec-
tion, they were deparaffined, and rehydrated using stand-
ard procedures. Epitope retrieval was performed by
incubating the slides in 10 mM sodium citrate buffer
(pH 6.0) for 20 min at 95-98 °C in a water bath. After
washing with PBS at room temperature, sections were
permeabilized with PBS with 0, 1% Triton X-100 (PBST)
and blocked for 1 h at room temperature with 5% donkey
serum in PSBT. Sections were incubated with primary
antibodies in blocking solution over night at 4 °C (rabbit
anti-proBDNF, 1:100 (Alomone); mouse anti-CEL, 1:100
(Trans Genic Inc); rabbit anti-ECDp75, 1:100 (Abcam);
goat anti-Sortilin, 1:100 (R&D System)). After washing the
sections were incubated for 2 h at room temperature with
the corresponding secondary antibodies in blocking
solution containing DAPI 1:2000 (donkey anti-goat Cy3,
1:500; donkey anti-rabbit Alexa488, 1:500; donkey anti-
mouse Cy3, 1:500 (all from Jackson Immunoresearch).
Blockage of anti-proBDNF antibody immunoreactivity
was performed by incubating the antigenic peptide with
the antibody in a proportion 10:1, during 2 h at room
temperature, before the immunohistochemistry proced-
ure. Fluorescence images were imaged on an Olympus
Bx51 fluorescence microscope or under a Fluo View
FV-1000 Olympus laser-scanning confocal microscope,
and micrographs were uniformly adjusted for levels,
brightness, and contrast in Adobe Photoshop.
Immunocytochemistry
Cells were fixed with 4% PFA in PBS for 30 min at room
temperature, permeabilized with TBST for 60 min at room
temperature and blocked with 5% donkey serum in TBST.
Primary antibodies were diluted in blocking solution and
incubated overnight at 4 °C (rabbit anti-human p75, 1:100
(Promega) to detect intracellular domain, rabbit anti-ECD
p75, 1:100 (Abcam) to detect the extracellular domain of
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p75NTR, goat anti-Sortilin, 1:100 (R&D System); rabbit
anti-TrkB, 1:100 (H-181, Santa Cruz Biotech.); goat
anti-SV2,1:100 (DSHB); mouse anti-βIII tubulin, 1:100
(Sigma); mouse anti-doublecortin, 1:100 (Cell Signaling),
rabbit anti-calbindin, rabbit anti-calretinin and parvalbu-
min,1:100 (Swant)). After washing samples were incubated
for 2 h at room temperature with the corresponding sec-
ondary antibodies diluted in blocking solution containing
DAPI 1:2000 (monkey anti-goat Cy3, 1:500; donkey
anti-rabbit Alexa488, 1:500; donkey anti-mouse Cy3, 1:500
(all from Jackson Immunoresearch)). Fluorescence images
were acquired on a confocal microscopy setup (Olympus
FV1000, 60X PlanApo using software Fluoview v.4.3) or
on an inverted fluorescence microscope (OlimpusIX71,
20X LCPlanFl).
Quantitative imaging
All microscope settings were set to collect images below sat-
uration and were kept constant for all images taken in one
experiment. Statistical significance (p values) was assessed
using the two-tailed Student’s t-test unless otherwise
indicated. Results were shown as the mean +/− standard
deviation (SD).
Statistical analysis
Statistical analysis of data was performed using SPSS
statistical software (SPSS for Windows, v.16, SPSS, Inc.,
Chicago, IL). Student’s t-test and One-way ANOVA ana-
lysis are used to identify significant differences.
Results
proBDNF expression and the ratio Sortilin/p75 are
increased in the hippocampus of AD patients
The hippocampus is one of the brain regions most af-
fected in the AD [29, 30]. Particularly vulnerable are a
group of neurons located in the hilus, also known as
hilear Mossy cells [33, 34]. We obtained brain samples
containing this region from AD patients and controls as
summarized in Table 1 and using antibodies directed
against the extracellular domain of p75 (p75ECD), Sorti-
lin and the pro-domain of BDNF, we performed im-
munofluorescence assays to determine the levels of
these proteins in the two groups. We observed that
fluorescence intensity for p75 in individual hileal cells of
AD brains was not significantly different on average
compared to control brains (Fig. 1b, f, i). However, Sorti-
lin fluorescence as well as the percentage of double posi-
tive cells for Sortilin and p75 increased significantly in
AD brains (Fig. 1c, g, i). We also observed an abundant
expression of proBDNF in the cytoplasm of the hileal
neurons of human hippocampus (Fig. 1k, m).
However, in AD brain samples, fluorescence intensity
of proBDNF was significantly higher than in control
brains (Fig. 1k, m, n). Next we asked whether proBDNF
and BDNF could be detected in the CSF of AD patients
and controls since this technique has been traditionally
used to study the expression profile of different markers
in alive individuals for the diagnostic and/or the prog-
nostic of neurodegenerative diseases. In this case, we an-
alyzed the CSF by western blot and used antibodies
against the mature form of BDNF that also detects the
proBDNF. Levels of mature BDNF (14 kDa band) in CSF
were very low compared to proBDNF (34 kDa band) and
required longer exposure times that were shown in a
separate panel (Fig. 1o). Densitometric analysis of the
two bands in 15 AD-affected patients and 15 control in-
dividuals (see Table 2 summarizing the demographic and
clinical characteristics of CSF donors) revealed that the
total levels of BDNF (proBDNF+BDNF) were similar be-
tween the two groups (Fig. 1p). However, in AD patients
we observed an increase of proBDNF associated with a
decrease of BDNF, compared to controls (Fig. 1o).
When we calculated the ratio proBDNF/BDNF in each
sample, we observed that the average ratio proBDNF/
BDNF was significantly higher in the CSF from AD pa-
tients (Fig. 1p). These results indicate that the CSF is a
reliable sample that recapitulates the changes in
proBDNF/BDNF expression that take place in the brain
of AD patients. In summary, we conclude that hileal
neurons of AD patients are more susceptible to cell
death due to the higher levels of proBDNF and Sortilin
expression and the higher proportion of cells express-
ing both p75 and Sortilin.
AGE modifications in proBDNF are increased in the
hippocampus and the CSF of AD patients
The increase of oxidative stress in the brain with aging
has been proposed to be a key factor triggering and/or
enhancing AD [1, 34]. The molecular mechanisms in-
volved are diverse and include post-traductional modifi-
cations of specific proteins. For instance, GO and MGO,
two highly reactive dicarbonyls that are increased during
OS, react with free amino groups of Lys, Arg and Cys
Table 1 Summary of the patients from whom hippocampal
samples were obtained and studied
N Age Gender Diagnostic Braak Stages Post-mortem delay /hours
1 46 F C 0 9
2 47 M C 0 5
3 24 F C 0 6
4 79 M AD V/B 5
5 82 F AD V/B 2
6 79 M AD V/C 7
7 85 F AD VI/C 12
C control, AD Alzheimer’s Disease, A, B and C Braak and Braak’s classification of
AD stages depending on amyloid plaques, 0-V Braak and Braak’s classification
of AD stages depending on the distribution and amount of
neurofibrillary tangles
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Fig. 1 Sortilin and proBDNF expression is increased in the hippocampal hilus in human control and AD-affected cases. Representative immunofluorescence
pictures stained with DAPI (a, e, j, l), ECDp75 (b, f), Sortilin (c, g) and proBDNF (k, m) at control and AD cases. i) Quantification of Sortilin immunoreactivity and
p75/Sortilin co-localization in the AD is significantly increased respect to the controls. n) Quantification of proBDNF expression is significantly increased in the
AD respect to the controls. Bars represent the mean of % positive cells ± SD. respect to DAPI stained cells. Positive cells are considered those with staining in
the whole cell body. 300 total cells from each sample from 5 control and 5 AD-affected cases are counted. o)Western blotting analysis of BDNF forms in
human CSF samples. The anti mBDNF antibody detect proBDNF (34 kDa) and mBDNF (14 kDa). Both panels correspond to the same WB. Lanes correspond to
different representative individuals. p) Densitometry analysis of immunodetected bands shows a significant increase proBDNF/mBDNF ratio in AD-affected
patients. Bars represent the mean of 9 control and 9 AD samples as the percentage of the highest value in each WB, corrected for the corresponding
densitometric values of the Coomassie-stained membrane. Scale bar =50 μm. * p<0,05, ** p< 0,01, two tailed Student’s “t” test
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residues leading to the formation of the AGE/ALE ad-
ducts CML, CEL and intermolecular crosslink [35, 36].
As we have previously reported, these modifications
affect proNGF during AD making the pro-neurotrophin
form of NGF more stable (as it cannot be converted to
mature NGF), which in turn increases cell death [28].
To determine whether proBDNF could be also modified
by reactive dicarbonyls in AD, we performed different
approaches. First, we studied the co-localization of
proBDNF and CEL by immunohistochemistry in the
hileal region of human hippocampal samples from con-
trols and AD-affected brains. We observed a remarkable
increase of CEL immunoreactivity in AD brains com-
pared to controls (Fig. 2c, g). Interestingly, almost all the
cells in the hillial region of AD patients with significant
CEL staining, also co-expressed proBDNF, while in con-
trol brains very few neurons displayed double immuno-
reactivity (Fig. 2b-d, f-h, i). These results strongly
suggested that proBDNF could be modified by reactive
dicarbonyls. In order to address this question directly we
performed a more specific assay. We immunoprecipi-
tated proBDNF from the CSF of controls and AD pa-
tients and analyzed the precipitates by Western blot
with an antibody against CEL. We found that the
proBDNF in the CSF from AD patients showed a prom-
inent CEL modification, around 6-fold on average, com-
pared to controls (Fig. 2j, k). Altogether these results
indicate that the proBDNF in AD patients displays AGE
post-traduccional modifications as consequence of an in-
crease of oxidative stress during neurodegeneration that
might prevent the action of convertases to produce ma-
ture BDNF (see below).
proBDNF modified in vitro by MGO induces neuronal
apoptosis and decreases neuron differentiation
In order to test the effects of the AGE modifications of
proBDNF induced by oxidative stress conditions on
neuron survival and differentiation, we treated recom-
binant proBDNF in vitro with reactive oxygen species
that react with Arg and Cys residues, resulting in the
formation of intermolecular modifications and cross-
overs of the protein (see Methods section). This
modified proBDNF (MproBDNF) was used to stimu-
late primary cultures of neurons along with mature
BDNF, unmodified proBDNF as well as an unrelated pro-
tein, Bovine Serum Albumin (BSA), modified in the same
way as the proBDNF (MBSA), as stimulation controls. In
these experiments we used differentiated hippocampal neu-
rons obtained from hippocampal NSCs plated on
laminin-coated plates (see Methods). At 1 day in vitro
(DIV), the neurons started to differentiate but it was be-
tween 4 and 7 DIV that the degree of maturation is signifi-
cative. In longer culture periods, neurons displayed a
complex degree of neuritogenesis and differentiation,
mainly in the mBDNF treated wells, which was difficult to
quantify. Differentiated neurons expressed doublecortin
(DCX), βIIItubulin, SV2, p75, Sortilin, TrkB and calretinin
(Fig. 3, Additional file 1: Figures S1-S3). These neurons,
however, were negative for parvoalbumin and calbindin
(Additional file 1: Figure S3), indicating that they are young
granular differentiated neurons. In control cultures treated
with mature BDNF for 6 DIV, neurons increased signifi-
cantly their differentiation compared to unstimulated cul-
tures, as demonstrated by β IIItubulin staining (Fig. 3a).
Interestingly, control stimulation with proBDNF, without
AGE modifications, did not increase apoptotic cell death
over basal levels; in contrast, it produced similar effects on
neuron differentiation as the mature BDNF (Fig. 3a, b).
However, stimulation with MproBDNF, produced a signifi-
cant increase of apoptosis and impaired neuron differenti-
ation (Fig. 3a, b, c). These effects were specific for the AGE
modified form of proBDNF (MproBDNF) since they were
not observed upon stimulation with MGO modified BSA
(MBSA) (Fig. 3a, b, c). These results suggest that proBDNF
is quickly converted into the mature form in culture, indu-
cing nearly the same effects as the BDNF, while the
MproBDNF, which is more resistant to the action of con-
vertases, is more stable and triggers the adverse effects as-
sociated with its pro-apoptotic activity.
CSF from AD patients induces neuronal apoptosis
through proBDNF/p75
Our results have shown so far that in AD patients there is
an increase of proBDNF/BDNF expression ratio as well as
Table 2 Demographic and clinical characteristics of the patients
from whom CSF samples were studied. Case (AD); control (C);
p (Student’s t-test)
Case(n = 15) C(n = 15) P
Male 4 (26.7%) 5 (33.3%) 0.7
Years 73.5 ± 12,1 70.5 ± 7,1 0.6
Age schooling 11.3 ± 5,0 11.3 ± 2,2 0.2
MMSE 19,1 ± 6,0 28,1 ± 1,8 0
Family history
Presenilin AD 2(13.3%) 0(0%) 0.14
EA > 65 years 3(20.0%) 5(33.3%) 0.4
Pathological history
Hypertension 6(40%) 8(53%) 0.46
Diabetes 3(20.0%) 2(13.3%) 0.6
Hypercolesterolemia 2(13.3%) 7(46.7%) 0.04
Depression 2(13.3%) 7(46.7%) 0.04
CSF AD Biomarkers pg/ml pg/ml
Amyloid β 386,128 856 ± 204 0
Total Tau 615 ± 270 281 ± 103 0.01
PhosphoTau 85 ± 28 55 ± 18 0
Fleitas et al. Molecular Brain           (2018) 11:68 Page 7 of 16
an increase of expression of some of the key signaling
elements involved in the pro-apoptotic effects of this
pro-neurotrophin. Moreover, we have observed that
proBDNF from AD patients displays AGE post-traduc-
tional modifications as a consequence of the increase of
the oxidative stress during neurodegeneration. Finally, our
in vitro experiments on differentiated neurons suggest
that these modifications produce a more stable form of
proBDNF, a process which can account for 1) the in-
creased levels of proBDNF in AD brains and CSF and 2)
the contribution of proBDNF to the cell death associated
with the disease. To evaluate further this hypothesis we
directly evaluate the effects of the proBDNF contained in
the CSF of AD patients and controls on differentiated
primary neurons, as above. Thus, we stimulated the cul-
tures for 6 DIV with CSF (substituting all the culture
media, see Methods) from control and AD patients and
stained the neurons with antibodies against p75ICD or
with DAPI staining, in order to assess the subcellular
localization of the protein by confocal microscopy and the
apoptotic cell death, respectively (Fig. 4a and Additional
file 1: Figure S3). Control CSF-treated neurons survived
and differentiated normally showing a basal rate of apop-
totic cell death of around 10% (Fig. 4a and c). A high
proportion of these neurons displayed a peripheral distri-
bution of p75 in the soma consistent with the presence of
the intact receptor in the plasma membrane (Fig. 4a, c). In
contrast, cultures treated with ADCSF showed an altered
Fig. 2 Hippocampal proBDNF is modiffied by AGE in AD human samples. Representative immunofluorescence pictures stained with DAPI
(a, e), anti-proBDNF (b, f), anti-CEL (c, g) at control and AD cases. i) Quantification of CEL and proBDNF co-localization in the AD is
significantly increased respect to the controls. Positive cells are considered those with staining in the whole cell body. Bars represent the
mean of 5 control and 5 AD samples as % colocalization of CEL and proBDNF respect to the total cell number (DAPI staining) ± SD . 300
total cells from each sample are counted. j) Representative image of Immunoprecipitation of proBDNF from CSF from controls and AD
patients analyzed by Western-blot with antibodies against CEL. k) Bars represent the mean of 9 control and 9 AD samples as the
percentage of the highest value in each WB, corrected for the corresponding densitometric values of the Coomassie-stained
membrane.Scale bar =50 μm . *** p < 0,001, two tailed Student’s “t” test
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morphology with impaired differentiation and a dramatic
increase the number of apoptotic nuclei (reaching 60%)
(Fig. 4a, c). Moreover, under ADCSF treatment, there was
a significant increase in the percentage of neurons with
nuclear immunoreacitvity for p75, indicating that the
20 kDa ICD fragment was shed and translocated to the
Fig. 3 proBDNF modified by MGO induces apoptosis in control mice differentiated hippocampal neural stem cells . a) Representative pictures of
neuronal primary culture treated for 6 days (7DIV) with: untreated (control), MGO modified BSA (MBSA), mBDNF, proBDNF and two doses of MGO
modified proBDNF (MproBDNF). DAPI staining (white) of nuclei shows apoptotic morphology (white arrow). Immunostaining with anti
βIIItubulin (red) show differentiation degree. b) Bars represent the quantification of apoptosis (by nuclei morphology), expressed as the
mean of % apoptosis ± SD of the total nuclei. c) The quantification of differentiation is expressed as the mean of % differentiation
(βIIItubulin immunoreactivity quantified by ImageJ, divided by the number of β III tubulin positive cells). Values represent the mean of
three independent experiments. Scale bar =25 μm . ** p < 0,01, *** p < 0,001 two tailed Student’s “t” test
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nucleus (Fig. 4a, d). The CSF from AD patients is known
to contain several other factors, such as Au, that might be
responsible for these neurotoxic effects. To determine
whether proBDNF present in the CSF of AD patients we
specifically immunodepleted the CSF samples from
proBDNF with specific anti-proBDNF antibodies coupled
to sepharose AG beads. Successful depletion was demon-
strated by Western blot with antibodies against proBDNF
(Fig. 4b). We then compared the effects of the immunode-
pleted CSF (CSFID) and the normal CSF from both, AD
patients and controls, in our neuron cultures after 6 DIV.
As shown in Fig. 4c and d, depletion of proBDNF
Fig. 4 Human proBDNF from CSF AD patients induces apoptosis in neuronal culture. a) Representative pictures of neuronal primary culture from
control mice Dentate Gyrus. Cells were treated for 6 days (7DIV) with human CSF from controls (control CSF) and from AD-affected patients
(ADCSF). DAPI staining of nuclei shows apoptotic morphology (white arrow). Immunofluorescence with anti p75 ICD domain (green) and anti
Sortilin (red). Inset indicate a higher magnification image of the boxed areas. White arrow in control CSF shows neurons with peripheral p75ICD
location. White arrows in AD CSF show p75ICD nuclear location. b) Representative image of western blot showing the levels of proBDNF in CSF
and in CSF immunodepleted with anti proBDNF (ID), from control and AD samples. c and d) Cells are treated with human 8 control CSF and 8
ADCSF, in both cases directly (CSF) or proBDNF immunodepleted (SCFID). c) Bars represent the quantification of apoptosis (by nuclei
morphology), expressed as the mean of % apoptosis ± SD of the positive cells for both p75 and Sortilin. d) Bars represent the quantification of
the mean of the % ± SD of neurons with the ICDp75 translocated to the nuclei (% ICD nuclear). Scale bar =50 μm . * p < 0,05, ** p < 0,01, two
tailed Student’s “t” test
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produced a remarkable reduction of the percentage of
apoptosis as well as the percentage of neurons with nu-
clear immunoreactivity for p75. Therefore, these results
indicate that the proBDNF in the CSF of AD patients is
biologically active and that it is the main responsible
of the pro-apoptotic effects triggered by AD CSF.
Moreover, these results strongly suggest that the ef-
fects of proBDNF in AD CSF are mediated by activa-
tion of p75 signaling.
APP/PS1 mutations increase p75 processing and
apoptosis induction
In the familiar AD, one of the most frequent targets of
inherited mutations is the presenilin-gamma secretase
complex [37]. Some of these mutations affect mainly prese-
nilin 1 (PS1) including the deletion of exon 9 (u9) or
M146 V [38]. These are supposed to be gain of function
mutations leading to an increase of protease activity [39].
The study of the pathogenic mechanisms underlying these
mutations and the development of AD has been focused on
several of the PS1 substrates, mainly Aβ [39]. Since p75 is
also a substrate of PS1 activity [18, 40], we hypothesized
that the harmful consequences of proBDNF on neuron sur-
vival and differentiation in AD, due to its higher stability as
a consequence of AGE modifications, could be boosted by
the effects of PS1 mutations on p75 signaling. In particular,
we were interested in ascertain whether the shedding of
p75, which requires PS1 activity, changes during AD and
whether these changes can sensitize the effects of
pro-neurotrophins. To test this hypothesis we set up pri-
mary neuron cultures from NSCs from heterozygous APP/
PS1 mice or from wild type littermates as controls (see
Methods). This APP/PS1 animal model has been widely
used in studies of neurological disorders of the brain, spe-
cifically AD, amyloid plaque formation, and aging [41].
After 6 DIV, when all the conditions are considered for the
analysis (regardless to the treatment), APP/PS1 cultures
does not show a % of apoptosis significantly different than
WT (One-way ANOVA p = 0.1). However under treatment
with MBSA (control), these transgenic APP/PS1 neurons
displayed higher percentage of apoptotic nuclei and higher
percentage of neurons with nuclear immunoreactivity for
p75 (Fig. 5a, b, c and Additional file 1: Figure S3). Interest-
ingly, stimulation with MproBDNF induced a stronger and
significant increase in cell death and p75 nuclear immuno-
reactivity in these transgenic neurons compared to controls
(Fig. 5a, b, c). We therefore conclude that PS1 mutations
involved in familiar AD potentiate the effects of proBDNF
on cell death most probably by increasing p75 signaling
and, in particular, p75ICD nuclear translocation.
Discussion
The pathogenic mechanisms underlying the develop-
ment of AD are complex and yet not fully understood.
Some important research lines have focused on the role
of neurotrophins in AD both, as regulating factors of cell
survival and cell death, involved in the pathogenesis
and/or the course of the disease, and as therapeutic tools
[2, 3]. Today, most of our knowledge about the role of
neurotrophins in AD comes from the study of the NGF
and its precursor form, proNGF. Thus, proNGF has
been reported to be increased during aging and AD in
vulnerable regions such as the hippocampus [42]. More-
over, the proNGF isolated from AD patients displays
higher neurotoxicity than proNGF from controls [27].
More controversial is the role of proBDNF/BDNF alter-
ations in the pathogenicity of the AD. In part, because
contradictory evidences were reported regarding the
expression and secretion of BDNF in its precursor form
[6, 43, 44]. It was suggested that these opposing results
reflect a more complex regulation of proBDNF process-
ing that depends on the regulation by third-parties such
as glial cells and plasmin inhibitors [45]. Indeed, BDNF
is more important for the maintenance and function of
central nervous system than NGF and thus, reduced
levels of BDNF, due to impairment of proBDNF process-
ing, could be involved in some aspects of the AD dis-
ease, such as depression, in addition to the neurotoxic
effects of the pro-neurotrophin [46].
In the present work we have addressed the role of
proBDNF and its pro-apoptotic signaling mechanisms in
AD. We showed that in brains from AD patients there is
an increase of the levels of proBDNF are increased, as
are also some of the key signaling components involved
in its pro-apoptotic effects, such as the co-receptor Sor-
tilin. We were also able to detect an increase of
proBDNF in the CSF of AD patients. Interestingly, this
increase of proBDNF in the CSF is associated with a de-
crease of BDNF. Moreover, we have demonstrated that
the proBDNF in the CSF from AD patients is highly
modified by oxidative stress and that the presence of this
AGE modified proBDNF induces apoptosis and impairs
differentiation on primary cultures of neurons. Finally,
we have shown that the damaging effects of proBDNF
can be potentiated by mutations commonly found in fa-
miliar forms of AD that affects PS1 protease activity.
This synergistic effect is due to the enhancement of p75
signaling, in particular of p75ICD internalization. The
present results further reveal the important role of neu-
rotrophin signaling in the development of the AD and,
in particular, our results provide evidence for the rele-
vance of the proBDNF/p75 pathway in the pathogenesis
and/or the course of AD. Thus, these results highlight
the importance of proBDNF/p75 signaling as potential
targets to develop novel pharmacological therapies to
fight AD.
During aging and especially during neurodegeneration
there is an increase of oxidative stress in the tissue that
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contributes to the pathogenesis of AD [1]. The neurotoxic
mechanisms involved, however, are not clearly understood.
Glyoxal (GO) and methylglyoxal (MG) are highly reactive
dicarbonyl formed during the metabolism that, in excess,
can increase ROS production and cause oxidative stress.
GO, and MGO can react with free amino groups of Lys,
Arg and Cys residues, leading to the formation of the AGE/
ALE adducts CML, CEL and intermolecular crosslink [47].
The relationship between protein carbonylation and
neurodegeneration (ND) has been widely established.
Changes in protein carbonyl samples from both disease ex-
perimental animal models and patients with neurodegener-
ation have been reported [48, 49]. Moreover, mass
spectrometry analysis of human brain homogenates has
shown that several AGE/ALE adducts, HNEL, CEL, CML
and Nε-(malondialdehyde)-lysine (MDAL) increase in ND
[1, 35]. Oxidative non-enzymatic modifications can also
affect protein structure and function by other means, for
Fig. 5 Apoptosis and p75 processing are increased in neuronal cultures from APP/PS1 animals. Primary cultures of differentiated mouse
hippocampal NSCs were treated for 6 days (7DIV) with MGO modified BSA (MBSA) or with MGO modified proBDNF (MproBDNF). a)
Representative immunofluorescence pictures of cells from WT and APP/P1 mice labeled with ICDp75 (green), βIIItubulin (red) and DAPI
(white). Inset represents a higher magnification image of the boxed areas indicating citoplasmatic (WT) and nuclear localization (APP/PS1)
of ICDp75. b) Bars represent the quantification of apoptosis (by nuclei morphology), expressed as the mean of % apoptosis ± SD of the
positive cells for both ICDp75 and βIIItubulin. c) Bars represent the mean of the % ± SD of neurons with the ICDp75 translocated to the
nuclei (% ICD nuclear). The values represent the mean of three independent experiments Scale bar =50 μm . ** p < 0,01, two tailed Student’s “t” test
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example increasing protein crosslinking and thus contrib-
utes to protein aggregation during ND [1]. These general
effects on protein structure might affect the function of
some proteins in a specific manner. In the present work,
we found that proBDNF co-localizes almost entirely with
CEL in AD samples and that the proBDNF isolated from
the CSF of AD patients display higher CEL modifications
than controls. We therefore suggest that the increase of
proBDNF in AD patients, in brain samples and in CSF, is
due to a higher stability of this precursor form resulting
from post-traductional modifications triggered by oxidative
stress that make this modified pro-neurotrophin more re-
sistant to be processed by convertases into the mature
BDNF. The target sequence for Furin and other convertases
(plasmin and metalloproteases) contains Lys, Arg, and Cys
residues that are indeed suitable sites for AGE/ALEs forma-
tion [50]. Similar results were obtained by our group when
we analyzed the role of proNGF/NGF in human hippocam-
pal samples from AD patients [16, 27, 28]. We cannot rule
out the possibility that AGE modified proBDNF could have
acquired gain-of-function effects independent of proBDNF
signaling. Nevertheless, since there is a strong correlation
between proBDNF levels in AD and p75 signaling (see
below) we rather favor the hypothesis these oxidative
stress-induced modifications makes the proBDNF more
stable and tip the balance in favour of cell death (increase
of proBDNF) at expenses of cell survival (decrease of
BDNF). Accordingly, we observed in the CSF of AD pa-
tients an increase of proBDNF that was associated with a
decrease of BDNF. In a more functional approach we dem-
onstrated that the CSF from AD patients, but not the CSF
from controls, induces apoptosis in a primary culture of dif-
ferentiated neurons obtained from NSCs from the Dentate
Gyrus. In contrast, CSF from control individuals main-
tained the survival and differentiation of these neurons up
to 6 DIV. Interestingly, depletion of proBDNF from AD
CSF samples reduced strongly the apoptotic effect of the
original AD CSF (apoptosis reduced from 40 to 20%), sug-
gesting that proBDNF is a main factor that triggers the
apoptotic effect of the AD CSF. The remaining 20% apop-
tosis could be due to other pro-apoptotic inducers such as
Aβ or proNGF (references). Finally, we propose that the ra-
tio proBDNF/BDNF measured in the in the CSF could be a
potential diagnostic marker for AD. To further validate this
approach, it would be interesting to measure the
proBDNF/BDNF ratio in the CSF of a larger cohort of pa-
tients and controls and analyze this ratio in regard to the
different stages of the disease.
BDNF genetic variation may affect the risk of develop-
ing AD [51]. One of these variations, proBDNFVal66Met,
impairs the normal processing of proBDNF resulting in
higher levels of expression of proBDNF [52]. The Val66-
Met polymorphism affects a particular step of proBDNF
processing that is sufficient to impair the formation of
enough levels of mature BDNF and trigger familiar de-
pression [46]. The mutation blocks proBDNF maturation
and affects activity-dependent secretion of BDNF and
human memory and hippocampal function [53, 54] and
worsens vulnerability to stress and response to antide-
pressants [55]. Despite the proBDNFVal66Me is able to
interact with p75 and Sortilin, altering the neuronal
morphology [52], a recent meta-analysis did not show
an association of the Val66Met polymorphism and the
risk of AD [56]. It is possible that the proBDNFVal66Met
is still partially processed reducing the neurotoxic effects
of the full proBDNF form.
Besides the increase of proBDNF levels in AD pa-
tients, we provide evidence for the existence of at least
two additional mechanisms that could potentiate the
neurotoxic action of proBDNF and accelerate the dis-
ease. First, we observed that the levels of Sortilin, the
co-receptor of p75NTR involved in the pro-apoptotic
effect of proBDNF, are increased in the hileal region of
the hippocampus of AD patients thus making the neu-
rons of this region more vulnerable to cell death. Sorti-
lin levels seem to be particularly sensitive to ageing and
neurodegeneration. For instance, Sortilin immunoreac-
tivity was described to be increased in ageing rodent
basal forebrain and sympathetic neurons while the
levels of p75NTR were either unchanged or reduced
[57]. On the other hand and similarly to our results,
Sortilin was shown to be increased in the temporal cor-
tical area of human AD brains as well as in brains of
6-months old PS1delta9 transgenic mice [58]. Interest-
ingly, this increase was suggested to be triggered by
amyloid beta1-42 (Aβ42) through the p75/RhoA signal-
ing pathway suggesting a potential physiological inter-
action of Aβ42, p75NTR and sortilin in AD [57]. From
all this data we propose that neurodegeneration in AD
patients may be enhanced by an increase of sortilin ex-
pression in neurons, probably induced by Aβ42, to-
gether with elevated levels of proBDNF in specific
regions.
Secondly, we found that proBDNF effects in AD can
also be enhanced by mutations found in familiar AD that
affect the convertase activity of the γ-secretase PS1. We
propose that these mutations make neurons more sensi-
tive to the pro-apoptotic effect of proBDNF by increas-
ing the susceptibility of p75 to be processed and induce
nuclear translocation of the p75ICD. Although in familiar
AD PS1 mutations are described to increase Aß42/40 ra-
tio, the effect of these mutations on its convertase activity
as gain or loss of function is controversial [39]. In the
present work, we have observed an increase of basal cleav-
age of p75 and an increase of p75ICD nuclear transloca-
tion and apoptosis (further induced by MproBDNF), in
neurons from the animal model of AD APP/PS1 bearing
the mutation Δ9 in PS1. Therefore we favor the idea that,
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at least the Δ9 deletion in PS1, behaves as a gain of func-
tion mutation.
More than fifty membrane proteins, including APP
and p75, are cleaved by the presenilin1- γ-secretase
complex [59, 60]. APP processing and Aβ production is
one of the hallmarks of AD [29]. On the other hand, the
cleavage of p75 and the production of the ICD fragment
that is translocated to the nucleus, is considered a key
step during the apoptotic signaling pathway triggered by
this receptor although the exact physiological effects of
p75ICD release depends on the neuronal subtype [18,
40]. Recently, experimental evidence indicates that p75
signaling, including cleavage and release of the ICD, is
indeed strongly related to AD, highlighting the central
role of p75 during AD pathogenesis [59]. Thus, several
mechanisms have been proposed involving p75 signaling
in AD. For instance, it was shown that Aβ is able to bind
to p75 and trigger activation of the receptor inducing
the cleavage of the ICD [60]. Moreover, amyloidogenesis
is aggravated by the interaction of beta-site amyloid pre-
cursor protein cleaving enzyme-1 (BACE1) with p75
upon the binding of Aβ to p75 [21]. In contrast, it was
shown that the p75ECD has a neuroprotective effect
against Aβ toxicity [61] and that transmembrane domain
of p75, has trophic effects by inducing phosphorylation
of TrKB [62]. Our results emphasize the important
contribution of p75 signaling, including p75ICD intern-
alization and apoptosis, in AD pathogenesis upon
AGE-modified proBDNF stimulation. More importantly,
our data provide a novel pro-apoptotic mechanism in
AD and involving p75 in which higher levels of cleavage
due to mutations in PS1 make these neurons more sen-
sitive to the adverse effects of AGE-modified proBDNF.
Moreover, we suggest that this is a general mechanism
in AD, also for the non-familiar, spontaneous form of
the disease, given the fact that Aβ is able to trigger p75
cleavage and p75ICD release and could therefore prime
p75 signaling for AGE modified proBDNF independenty
of PS1 mutations.
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